Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences. At the Wells Fargo Healthcare Conference at Encore Boston Harbor in Boston, the company will hold 1×1 meetings on September 8 with CEO Ahmed Mousa. At the Cantor Global Healthcare Conference at the Waldorf Astoria New York, Mousa will join a fireside chat and 1×1 meetings on September 11 from 9:45–10:15 AM ET, which will be available via webcast.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The latest conference schedule can be viewed against VCRE’s prior conference-related reactions of -1...
Analysis
The latest conference schedule can be viewed against VCRE’s prior conference-related reactions of -1.48%, -8%, and -7.54%. Those observations add historical context, while low short positioning and no recent insider activity provide additional risk context.
Investor forum participation announcement; shares declined 7.54% over the following 24 hours.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Vicore’s prior conference-related announcements were followed by negative 24-hour price reactions despite neutral informational content.
Key Terms
idiopathic pulmonary fibrosis, orphan drug, fast track designation
3 terms
idiopathic pulmonary fibrosismedical
"disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis"
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
orphan drugregulatory
"has received Orphan Drug and Fast Track designation"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
fast track designationregulatory
"has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences:
Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, Mass. Format: 1×1 meetings Participation Date: Tuesday, September 8, 2026 Participant: Ahmed Mousa, Chief Executive Officer
Cantor Global Healthcare Conference Location: Waldorf Astoria New York, New York, N.Y. Format: Fireside chat and 1×1 meetings Fireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ET Webcast: Link Participant: Ahmed Mousa, Chief Executive Officer
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
When will Vicore Pharma (VCRE) attend the Wells Fargo Healthcare Conference in 2026?
Vicore Pharma will participate in the Wells Fargo Healthcare Conference on Tuesday, September 8, 2026. According to the company, the event will take place at Encore Boston Harbor in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.
What is Vicore Pharma presenting at the Cantor Global Healthcare Conference 2026 (NASDAQ:VCRE)?
Vicore Pharma will join a fireside chat and 1×1 meetings at the Cantor Global Healthcare Conference. According to the company, the fireside chat is scheduled for Friday, September 11, 2026, from 9:45–10:15 AM ET at the Waldorf Astoria New York.
How can investors access Vicore Pharma’s Cantor Global Healthcare Conference 2026 webcast?
Vicore Pharma states that the Cantor fireside chat on September 11, 2026, from 9:45–10:15 AM ET will be available via webcast link. Investors can use the provided webcast link to listen to CEO Ahmed Mousa’s discussion.
Who will represent Vicore Pharma (VCRE) at the September 2026 healthcare conferences?
Vicore Pharma will be represented by Chief Executive Officer Ahmed Mousa at both the Wells Fargo and Cantor healthcare conferences. According to the company, he will participate in 1×1 meetings and a fireside chat with investors and stakeholders.
What is Vicore Pharma’s lead program mentioned in the September 2026 conference announcement?
Vicore Pharma’s lead program is buloxibutid, an oral angiotensin II type 2 receptor agonist. According to the company, it has Orphan Drug and Fast Track designations from the U.S. FDA and is being studied in the global 52-week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis.
On which stock exchanges is Vicore Pharma listed and under what symbols?
Vicore Pharma is listed on Nasdaq Stockholm as VICO and on Nasdaq US as VCRE. According to the company, it is a clinical-stage biopharmaceutical business focused on angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.
